Muscular Dystrophy

Muscular Dystrophy (MD) describes a heterogeneous group of inherited myopathies characterized by progressive muscle weakness and wasting due to defective structural or membrane-associated proteins in skeletal muscle. The term encompasses a family of disorders unified by a dystrophic muscle biopsy, muscle fiber necrosis, regeneration, and replacement by fat and fibrous connective tissue, but distinguished by genetic etiology, mode of inheritance, age at onset, and pattern of muscle involvement.

Also Called / Synonyms

• Duchenne Muscular Dystrophy (DMD): Duchenne dystrophy, pseudohypertrophic muscular dystrophy, DMD (MIM #310200)
• Becker Muscular Dystrophy (BMD): Becker dystrophy, benign pseudohypertrophic muscular dystrophy, BMD (MIM #300376)
• Facioscapulohumeral Muscular Dystrophy (FSHD): Landouzy-Dejerine dystrophy, FSHD1/FSHD2 (MIM #158900, #158901)
• Myotonic Dystrophy (DM): Steinert disease, DM1/DM2 (MIM #160900, #602668)
• Limb-Girdle Muscular Dystrophy (LGMD): LGMD1 (autosomal dominant), LGMD2 (autosomal recessive), now reclassified as LGMD D/R with a letter suffix denoting the gene (e.g., LGMDR1 for calpainopathy)
• Congenital Muscular Dystrophy (CMD): CMD with structural brain involvement (e.g., Walker-Warburg syndrome, muscle-eye-brain disease, Fukuyama CMD) or without (e.g., Ullrich CMD, Bethlem myopathy) ^[2]A1c[11]C4
• Emery-Dreifuss Muscular Dystrophy (EDMD): Emery-Dreifuss syndrome, EDMD1 (X-linked), EDMD2/3 (autosomal dominant/recessive)
• Oculopharyngeal Muscular Dystrophy (OPMD): OPMD (MIM #164300)
• McLeod Syndrome: McLeod neuroacanthocytosis syndrome (MIM #314850) ^[8]D5

Classification by Genetic and Clinical Axes

The modern taxonomy organizes MD along three intersecting axes: inheritance pattern, gene/protein defect, and clinical phenotype. This framework allows clinicians to navigate from a patient's presenting weakness pattern to a targeted genetic diagnosis and prognostic counseling.

Inheritance and Gene-Product Nomenclature

Key Nomenclature Changes: LGMD Reclassification (2018)
The 2018 LGMD reclassification abandoned the numeric LGMD1/LGMD2 system in favor of a letter-based designation: LGMD D (Dominant) or LGMD R (Recessive) followed by a letter indicating the causative gene product ^[15]B2b. For example, calpainopathy (formerly LGMD2A) is now LGMDR1, and DNAJB6-related LGMD (formerly LGMD1D) is LGMDD1. This system eliminates confusion between historically numbered subtypes and aligns with the genetic paradigm.

Clinical Significance

MD collectively is the most prevalent group of inherited neuromuscular disorders, with DMD affecting approximately 1 in 3,500 to 5,000 live male births; the combined prevalence across all subtypes is estimated at 18-25 per 100,000. Respiratory and cardiac failure are the leading causes of death across DMD, BMD, and many LGMD and CMD subtypes, making early identification and multidisciplinary care essential for survival and quality of life.

Pearl: Muscular dystrophy must be distinguished from other causes of progressive muscle weakness by integrating inheritance pattern, distribution of weakness (proximal vs distal, facial vs limb-girdle), age at onset, and creatine kinase elevation. The 2018 LGMD reclassification and the addition of SNUPN-related LGMD underscore that new genetic discoveries continue to refine both taxonomy and therapeutic strategies ^{[10]C4[15]B2b}.

All muscular dystrophies converge on a final common pathway of progressive muscle fiber degeneration and regeneration, but the initiating molecular event, and therefore the neuroanatomic pattern of weakness, differs by subtype. The pathogenic mechanism for each major form can be traced to a disruption of the dystrophin-associated glycoprotein complex (DGC), the nuclear membrane, or RNA metabolism, each of which produces a characteristic signature of muscle involvement.

The Dystrophin-Glycoprotein Complex as a Central Node

The DGC is a multimeric complex that links the intracellular cytoskeleton to the extracellular matrix, providing mechanical stability to the sarcolemma during muscle contraction and relaxation. Dystrophin, a 427-kDa rod-shaped protein encoded by the DMD gene, anchors actin filaments at its N-terminus to β-dystroglycan at its C-terminus. β-dystroglycan in turn binds α-dystroglycan, an extracellular receptor for laminin-α2 and other matrix proteins ^[28]D5[29]D5. Loss of any DGC component disrupts this linkage, rendering the sarcolemma vulnerable to contraction-induced micro-tears. The resulting membrane instability triggers a cascade: calcium influx activates proteases (calpains), mitochondrial dysfunction generates reactive oxygen species, and repeated cycles of necrosis and regeneration exhaust the satellite cell pool, culminating in fibrofatty replacement of muscle ^[28]D5[48]D5.

Duchenne and Becker muscular dystrophy arise from DMD mutations that ablate (Duchenne) or reduce (Becker) dystrophin ^{[17]A1b[23]C4[24]B2b}. The reading-frame rule, out-of-frame mutations produce Duchenne, in-frame produce Becker, is supported by the observation that transcriptional slippage can restore a partial reading frame and convert a predicted Duchenne genotype to a milder Becker phenotype ^[23]C4. Micro-dystrophin gene therapy, delivered by adeno-associated virus (AAV) vectors, aims to rebuild a functional DGC by expressing a shortened but mechanically competent dystrophin ^{[19]B2b[37]C4[47]D5}.

Limb-girdle muscular dystrophy (LGMD) subtypes result from mutations in individual DGC components other than dystrophin. In α-sarcoglycanopathy (LGMDR3), loss of α-sarcoglycan destabilizes the DGC, and transcriptomic analysis of patient muscle reveals upregulation of inflammatory and fibrotic pathways that correlate with disease severity ^[30]B3b. TCAP mutations (LGMDR7) cause telethonin deficiency, which disrupts titin anchoring at the Z-disk and leads to abnormal mitochondrial positioning; AAV-mediated TCAP delivery in a Tcap-/- mouse model restored mitochondrial localization and improved muscle function ^[33]D5.

Dystroglycanopathies: Disrupted Extracellular Matrix Signaling

Dystroglycanopathies are caused by defective O-mannosylation of α-dystroglycan, impairing its ability to bind laminin, agrin, and neurexin ^[21]C4[22]D5. Mutations in POMT1, POMT2, POMGNT1, FKTN, or FKRP reduce glycosyltransferase activity, with residual enzyme activity inversely correlated to clinical severity: near-zero activity causes Walker-Warburg syndrome (congenital muscular dystrophy with cobblestone lissencephaly and ocular defects), whereas partial activity permits milder LGMD phenotypes ^[11]C4[21]C4. The neuroanatomic correlate of severe dystroglycanopathy is a breach of the glia limitans, the outermost layer of the brain, during development, allowing neuroglial overmigration into the arachnoid space and producing the pathognomonic cobblestone cortex ^[11]C4.

Facioscapulohumeral Muscular Dystrophy: DUX4 Derepression and p53-Dependent Myopathy

FSHD has a unique two-step genetic mechanism: (1) a permissive 4q35 haplotype that includes a polyadenylation signal for the DUX4 transcript, and (2) either contraction of the D4Z4 macrosatellite repeat array to 1-10 units (FSHD1) or loss-of-function mutations in SMCHD1 or DNMT3B (FSHD2), resulting in D4Z4 chromatin relaxation and inappropriate DUX4 expression in skeletal muscle ^{[20]C4[26]C4[36]B3b[43]D5}. DUX4, a double-homeobox transcription factor, activates p53-dependent apoptosis and a cascade of pro-apoptotic genes, including caspase-3 and BAX ^[43]D5. Sporadic DUX4 expression in a minority of myonuclei is sufficient to drive muscle atrophy, and 3D tissue-engineered models confirm that DUX4 target-gene expression disrupts sarcolemmal organization and reduces contractile force ^{[32]D5[39]B3b}. The retinal vasculopathy seen in FSHD, copper-wire arterioles and telangiectasias, likely stems from the same DUX4-driven vascular vulnerability in a more accessible tissue ^[27]B3b.

Myotonic Dystrophy : RNA Toxicity and Alternative Splicing Dysregulation

Myotonic dystrophy type 1 (DM1) is caused by a CTG trinucleotide repeat expansion in the 3′ untranslated region of DMPK ^[35]B3b. The transcribed CUG repeats adopt a stable hairpin structure that sequesters muscleblind-like (MBNL) splicing factors into nuclear RNA foci, while simultaneously upregulating CELF1. The net effect is a reversion to fetal splice patterns in adult mRNA transcripts; for example, mis-splicing of the chloride channel CLCN1 reduces its expression and underlies myotonia, while mis-splicing of cardiac troponin T (TNNT2) contributes to cardiomyopathy ^{[35]B3b[40]B3b}. Importantly, some alternative splicing dysregulation seen in DM1 may be a secondary consequence of muscle regeneration rather than a primary pathogenic event, as similar patterns appear in other muscular dystrophies ^[40]B3b. In the brain, choroid plexus epithelial cells are particularly vulnerable to MBNL sequestration, leading to altered cerebrospinal fluid composition and contributing to hypersomnia and executive dysfunction ^[35]B3b.

Congenital Muscular Dystrophy: Laminin-α2 Deficiency and Apoptosis

Congenital muscular dystrophy type 1A (MDC1A) results from loss-of-function mutations in LAMA2, encoding laminin-α2 ^[42]D5. Absence of this extracellular matrix ligand for α-dystroglycan destabilizes the DGC at the sarcolemma and triggers inappropriate apoptosis independent of mechanical injury. In Lama2-null mice, doxycycline , a tetracycline with anti-apoptotic properties, extended lifespan and improved neuromuscular function, implicating the apoptotic cascade as a modifiable pathogenic node ^[42]D5.

Mitochondrial and Neuroanatomic Patterns

Across subtypes, mitochondrial dysfunction and abnormal myonuclear positioning emerge as common downstream effectors ^{[33]D5[46]D5[48]D5}. In DMD, myonuclei display hypermotility and fail to establish proper nuclear domains, an effect driven by AMPK dysregulation and linked to the scaffold protein NuMA1 ^[48]D5. In LGMD R7 (TCAP), telethonin deficiency disrupts the linkage of mitochondria to the sarcomere, causing mitochondrial clustering at the fiber periphery ^[33]D5. These findings indicate that the DGC and its associated proteins not only stabilize the sarcolemma but also organize intracellular organelle positioning, and that loss of this organization contributes to muscle dysfunction.

A systematic overview is provided in Table 1.

Table 1. Pathogenetic Mechanisms by Muscular Dystrophy Subtype

Pearl: Every clinical feature, from cobblestone lissencephaly in dystroglycanopathy to myotonia in DM1, traces directly to a discrete molecular event: sarcolemmal instability, DUX4-driven apoptosis, or RNA spliceopathy. Recognizing this chain of causation guides rational therapeutic targeting, as demonstrated by AAV-mediated micro-dystrophin gene therapy ^{[19]B2b[47]D5}, exon-skipping oligonucleotides ^{[17]A1b[24]B2b[31]D5}, and anti-apoptotic strategies ^[42]D5.

Incidence and Prevalence

Muscular dystrophies collectively affect 1 in 3,000 to 1 in 6,000 individuals worldwide, making them the most common inherited myopathies encountered in neuromuscular practice ^[64]B2c. Duchenne muscular dystrophy (DMD) alone has an incidence of 1 per 5,000 male newborns globally, a figure confirmed by newborn screening programs using dried blood spot creatine kinase (CK) measurement ^[73]B2b. Becker muscular dystrophy (BMD) is roughly three to five times less common, with an estimated incidence of 1 per 15,000 to 1 per 20,000 male births. Facioscapulohumeral muscular dystrophy (FSHD) shows a prevalence of 12 per 100,000 in the Netherlands, with an incidence of 0.3 per 100,000 person-years, making it the third most common adult-onset muscular dystrophy ^[56]B2c. Myotonic dystrophy type 1 (DM1) is the most common adult-onset form, with a prevalence of approximately 1 in 8,000 in European populations ^[64]B2c. Limb-girdle muscular dystrophies (LGMDs) collectively affect an estimated 1 in 14,500 to 1 in 50,000 individuals, with significant geographic variability ^[64]B2c. Congenital muscular dystrophy (CMD) is rarer, with a point prevalence of 0.56 per 100,000 in Italy ^[60]B2c.

Demographic and Geographic Distribution

DMD and BMD show an X-linked recessive inheritance pattern confined almost exclusively to males, though symptomatic female carriers are recognized. The disorder shows no ethnic predilection; however, regional differences in genetic diagnosis reflect variation in founder mutations and access to genetic testing. In Qatar, 97% of DMD/BMD patients are male, with a median age at diagnosis of 4.5 years, consistent with global data ^[75]B2b. FSHD shows a slight female predominance in registry studies, likely due to ascertainment bias and milder presentation in females ^[57]C4. Myotonic dystrophy shows equal sex distribution. CMD in Italy is most commonly associated with α-dystroglycan glycosylation deficiency (40%), followed by laminin α2 deficiency (24%) and collagen VI deficiency (20%) ^[60]B2c; this distribution may vary in other populations.

Temporal Trends

Incidence of most muscular dystrophies is stable, but prevalence is rising due to improved survival. For DMD, the median survival has extended from the late teens in the 1970s to approximately 30 years in current cohorts, driven by corticosteroid use and noninvasive ventilatory support. FSHD mortality has been historically underestimated; a systematic review found limited but consistent evidence of excess mortality, particularly from respiratory failure in severely affected individuals ^[68]B2a.

Etiologic Classification

Muscular dystrophies are genetically heterogeneous. The primary etiologic categories include:

Risk Factors

Most risk factors for muscular dystrophy are non-modifiable. The key determinants are:

Modifiable factors are limited. Glucocorticoid use in DMD, while beneficial for muscle function, increases fracture risk; early monitoring of bone mineral density is recommended ^[70]B2b. A study of myocardial injury after gene replacement therapy for DMD reported immune-mediated myocarditis in 2.5% of treated patients (95% CI 0.8-6.1), a treatment-emergent risk rather than a baseline factor ^[69]A1a.

Cancer Risk

Patients with myotonic dystrophy have an elevated risk of certain cancers. A Swedish register-based cohort study found an overall increased cancer risk in myotonic dystrophy (hazard ratio 1.5, 95% CI 1.2-1.9), driven primarily by endometrial cancer and thyroid cancer ^[54]B2b. A separate Japanese study confirmed a significantly higher incidence of endometrial cancer or atypical endometrial hyperplasia in myotonic dystrophy compared to other muscular dystrophies (13.9% vs. 1.2%; p = 0.002) ^[74]B2b. For DMD and BMD, cancer risk was not significantly elevated in the Swedish cohort ^[54]B2b.

Spectrum of Immune-Mediated Myocardial Injury After Gene Therapy

AAV-based gene replacement therapy (e.g., delandistrogene moxeparvovec for DMD) carries a risk of immune-mediated myocardial injury, particularly in patients with preexisting anti-AAV antibodies. A meta-analysis reported an incidence of 8% (95% CI 5-12%) for any cardiac adverse event, with 2.5% meeting criteria for myocarditis ^[69]A1a. The timing is typically within the first 30 days post-infusion, requiring careful monitoring and prophylactic immunosuppression.

Pearl: Muscular dystrophies are rare but collectively affect 1 in 3,000 individuals; DMD is the most common childhood form and FSHD the most common adult-onset form after myotonic dystrophy. Family history remains the strongest risk factor, but approximately 30% of DMD cases arise from de novo mutations, underscoring the importance of genetic testing even without a known family history.

The clinical presentation of muscular dystrophy is best understood as a direct translation of the underlying molecular deficit into a predictable pattern of muscle weakness, wasting, and associated systemic involvement. The history and examination, when approached systematically, often point to a specific subtype before any genetic testing is performed.

Presenting Symptoms

The mode of onset is the single most important diagnostic clue. In Duchenne muscular dystrophy (DMD), symptoms emerge in early childhood, typically before age 5, with a waddling gait, frequent falls, and difficulty climbing stairs or rising from the floor ^[84]B2b. Parents often first note a peculiar "toe-walking" or an inability to keep up with peers. The classic Gowers maneuver (using the hands to "walk" up the thighs to stand) is pathognomonic when present. In Becker muscular dystrophy (BMD), onset is later, often in adolescence or early adulthood, with proximal weakness that is milder and more slowly progressive; calf hypertrophy and myalgia are common ^[84]B2b. Myotonic dystrophy type 1 (DM1) presents with a characteristic triad: grip myotonia (inability to quickly relax a handshake), distal weakness, and early cataracts ^[89]D5. By contrast, facioscapulohumeral muscular dystrophy (FSHD) typically presents in adolescence or young adulthood with asymmetric weakness of the facial muscles (inability to whistle, close the eyes fully, or puff out the cheeks) and scapular fixators (prominent scapular winging) ^[57]C4[81]C4. Limb-girdle muscular dystrophies (LGMD) present with a pelvic- or shoulder-girdle-predominant weakness, often in the second to fourth decades, with the specific pattern depending on the gene involved ^[10]C4[85]C4. Congenital muscular dystrophies present at birth or within the first year of life with hypotonia, delayed motor milestones, and often joint contractures ^[2]A1c[83]C4.

The progression timeline is crucial: DMD patients lose ambulation by a median age of 12 years without corticosteroid treatment, whereas BMD patients remain ambulatory beyond age 16 and often into adulthood ^[84]B2b. FSHD progresses slowly over decades, with approximately 20% of patients becoming wheelchair-dependent ^[57]C4.

Neurological Examination Findings

Motor System

Inspection begins with the patient standing and walking. Calf hypertrophy is a classic sign in DMD and BMD, reflecting pseudohypertrophy from fibrofatty replacement of muscle ^[84]B2b. In FSHD, Beevor sign, upward migration of the umbilicus during neck flexion, is a specific finding, present in over 40% of patients, due to selective weakness of the lower rectus abdominis ^[77]C4. Scapular winging is prominent in FSHD and can be elicited by asking the patient to push against a wall; asymmetry is hallmark ^{[81]C4[82]B2b}. In LGMD2A (calpainopathy), scapular winging and early contractures are also typical ^[85]C4.

Manual muscle testing using the Medical Research Council (MRC) scale reveals a proximal > distal pattern in DMD, BMD, and most LGMDs. DM1 shows a distal > proximal pattern with intrinsic hand muscle wasting. FSHD shows selective weakness: facial muscles (orbicularis oris and oculi), scapular stabilizers (serratus anterior, trapezius), and humeral muscles (biceps, triceps) are affected first, while deltoid and forearm muscles are relatively spared ^[57]C4[81]C4. In dysferlinopathy (LGMD2B), calf weakness and inability to stand on tiptoes are early signs ^[87]B2b.

Reflexes and Sensory System

Deep tendon reflexes are normal or reduced in proportion to weakness in most dystrophies; they are never hyperreflexic (which would suggest a neurogenic cause such as ALS or spinal muscular atrophy). Sensory examination is entirely normal in all primary muscular dystrophies; a sensory deficit strongly suggests an alternative diagnosis such as a neuropathy or myelopathy.

Cranial Nerves and Cardiac Examination

Facial weakness is a red flag for FSHD, DM1, and congenital myotonic dystrophy. Ptosis is absent in FSHD but common in myasthenia gravis (which can co-occur with FSHD in rare cases ^[94]C4). Ophthalmoplegia is absent in most dystrophies but prominent in mitochondrial myopathies. Cardiac examination is mandatory in DMD, BMD, and Emery-Dreifuss muscular dystrophy (EDMD): in DMD, dilated cardiomyopathy develops in nearly all patients after age 18, and arrhythmias or heart failure may be the first sign in BMD or EDMD ^{[79]C4[84]B2b}. Neck flexion weakness and contractures are key in EDMD ^[79]C4.

Phenotypic Variants

Red Flags

Certain symptoms demand immediate action. Respiratory insufficiency, manifesting as orthopnea, morning headaches, or excessive daytime sleepiness, is a medical emergency in any dystrophy patient. Forced vital capacity (FVC) below 50% of predicted is a threshold for initiating discussions about noninvasive ventilation; FVC < 15 mL/kg requires consideration of intubation ^[83]C4. Acute-onset severe myalgia or dark urine may signal rhabdomyolysis , a presentation of dysferlinopathy or GMPPB-related disease ^{[78]C4[87]B2b}. Cardiac syncope or palpitations in any patient with DMD, BMD, EDMD, or DM1 warrants urgent cardiology evaluation for arrythmias or cardiomyopathy ^{[79]C4[84]B2b}. Suicidal ideation has been reported in BMD, likely related to the psychosocial burden of progressive disability; it requires prompt psychiatric intervention ^[91]C4.

Atypical Presentations

Some dystrophies defy the classic pattern. Isolated dilated cardiomyopathy without significant muscle weakness can be the sole manifestation of BMD or fukutin gene (FKTN) mutations ^{[80]C4[84]B2b}. Recurrent rhabdomyolysis without fixed weakness is an established presentation of dysferlinopathy and GMPPB-related dystroglycanopathy ^{[78]C4[87]B2b}. HyperCKemia (incidentally found on routine lab testing) in an asymptomatic individual may be the earliest sign of a dystrophy, particularly BMD or LGMD, and warrants workup. Cognitive or behavioral issues (intellectual disability, ADHD, or autism spectrum disorder) can precede or overshadow the motor symptoms in DMD, especially when the mutation affects brain dystrophin isoforms (Dp140, Dp71) ^[86]C4. Respiratory failure as the presenting symptom, without significant limb weakness, has been reported in rigid spine syndrome ^[34]C4.

Pearl: The pattern of weakness, proximal vs distal, symmetric vs asymmetric, presence of calf hypertrophy or scapular winging, and age at onset, narrows the differential diagnosis to one or two dystrophy subtypes before laboratory testing; Beevor sign, when present, is nearly pathognomonic for FSHD ^[77]C4[81]C4.

The diagnostic pathway for muscular dystrophy begins with a high index of clinical suspicion, progressive, symmetric proximal weakness, calf pseudohypertrophy, Gowers sign, or a family history of X-linked or autosomal inheritance, and moves through a deliberate sequence of biochemical, genetic, and electrophysiological tests designed to confirm the subtype and guide management . The goal is a specific genetic diagnosis, which is now the gold standard for nearly all forms ^{[95]A1c[96]A1a}.

First Step: Serum Creatine Kinase (CK)

Serum CK is the gatekeeper. In Duchenne muscular dystrophy (DMD), CK is dramatically elevated, often 50 to 100 times the upper limit of normal, when measured in a non-traumatized, ambulant boy. In Becker muscular dystrophy (BMD), values are also high but less extreme, typically 10 to 50 times normal. Limb-girdle muscular dystrophies (LGMD) show moderate elevations (5 to 30 times normal), while facioscapulohumeral muscular dystrophy (FSHD) often presents with only mild or even normal CK levels ^{[95]A1c[96]A1a}. A normal CK in the setting of suggestive weakness should prompt re-evaluation for myotonic dystrophy , congenital myopathy, or a neurogenic cause. For newborns, CK screening on dried blood spots can identify DMD before symptoms appear, with a sensitivity of 98% to 100% for the initial assay ^{[119]D5[126]D5}.

Gold-Standard Test: Genetic Confirmation

The gold-standard diagnostic test for muscular dystrophy is molecular genetic testing, specifically, a targeted next-generation sequencing (NGS) panel or whole-exome sequencing (WES) that covers all known dystrophy-associated genes. For DMD/BMD, direct sequencing of the DMD gene (79 exons) detects deletions, duplications, and point mutations with a sensitivity of 99% ^{[95]A1c[108]A1c}. For FSHD1, Southern blot or molecular combing to detect a contraction of the D4Z4 repeat array on chromosome 4q35 is first-line; this has a sensitivity of 95% and specificity of >99% ^{[1]A1c[128]C4}. For LGMD, a comprehensive NGS panel now supersedes muscle biopsy as the initial genetic test, achieving a diagnostic yield of 35% to 45% in unselected cohorts ^{[96]A1a[113]D5[117]C4}. Muscle biopsy is reserved for cases where genetic testing is unrevealing or variants of uncertain significance require protein-level confirmation.

Electrodiagnostic Studies: NCS/EMG

Nerve conduction studies (NCS) and electromyography (EMG) differentiate myopathic from neurogenic disorders. In muscular dystrophy, NCS is typically normal, excluding a peripheral neuropathy . Needle EMG reveals small, short-duration, polyphasic motor unit potentials with early recruitment, the hallmark of a myopathic process. In addition, myotonic discharges (waxing-and-waning, repetitive potentials on needle insertion) are pathognomonic for myotonic dystrophy (DM1/DM2) and can also be seen in some forms of FSHD and Pompe disease ^{[90]C4[95]A1c[96]A1a}. The role of EMG has narrowed with the adoption of genetic testing, but it remains useful when clinical suspicion is low or when a pattern of myotonia directs DMPK or CNBP testing.

Muscle Biopsy: When and How

Muscle biopsy is no longer first-line but retains critical value when:

• Genetic testing is negative or identifies variants of unknown significance.
• The presentation is atypical or rapidly progressive.
• A congenital muscular dystrophy (CMD) subtype is suspected, where immunohistochemistry for laminin α2, collagen VI, or α-dystroglycan can guide targeted gene sequencing ^{[2]A1c[59]C4[66]C4}.
• For DMD, a complete absence of dystrophin staining (with antibodies to the N-terminal, rod, and C-terminal domains) distinguishes DMD from BMD, where dystrophin is reduced in quantity or size ^[95]A1c.
• For FSHD, biopsy may show nonspecific myopathic changes with or without inflammatory infiltrates, but it is not required for diagnosis ^[1]A1c.

Imaging: Muscle MRI

Muscle MRI of the pelvis, thighs, and lower legs provides a non-invasive roadmap that can narrow the differential before genetic testing. Distinct patterns are recognized:

• DMD/BMD: Selective involvement of the glutei, adductors, and quadriceps with relative sparing of the gracilis and sartorius; fatty replacement begins in the posterior thigh ^{[95]A1c[108]A1c}.
• LGMD (calpainopathy, dysferlinopathy): Calpain-deficient LGMD shows selective involvement of the adductors, hamstrings, and glutei with relative sparing of the rectus femoris. Dysferlinopathy (LGMD R2) presents with posterior calf involvement ^{[96]A1a[127]C4}.
• FSHD: A characteristic pattern of asymmetric involvement of the trapezius, serratus anterior, and abdominal muscles; the iliopsoas is often spared early ^[106]C4.
• Collagen VI-related myopathies (Bethlem, Ullrich CMD): A rim of fatty infiltration around the vastus lateralis and rectus femoris, the "central shadow" sign, is highly suggestive ^{[102]C4[127]C4}.
• Myotonic dystrophy type 1: Early involvement of the temporalis, sternocleidomastoid, and distal leg muscles ^[118]C4. MRI findings do not replace genetic diagnosis but can increase pre-test probability and shorten the diagnostic odyssey.

Special Tests: EEG, LP, and Neuroimaging in Specific Subtypes

EEG is not routine in muscular dystrophy. It is indicated only in LAMA2-related CMD, where occipital epilepsy occurs in 36% of patients (often with visual aura and autonomic signs), and in rare cases of DMD with refractory seizures ^[120]C4.

Lumbar puncture (LP) has no role in the diagnosis of muscular dystrophy except to exclude alternative causes (e.g., inflammatory myopathy, meningeal disease) when presentation is atypical.

Brain MRI is relevant in:

• CMD: White matter abnormalities, cobblestone lissencephaly, or cerebellar cysts are seen in α-dystroglycanopathies and LAMA2 deficiency, distinguishing them from other CMDs ^[2]A1c[59]C4.
• Myotonic dystrophy type 1: Cerebral atrophy and white matter hyperintensities, particularly in the anterior temporal lobes, correlate with cognitive symptoms ^[118]C4.
• FSHD: No brain abnormalities are expected; a normal brain MRI supports the diagnosis.

Algorithm: Stepwise Diagnostic Pathway

1. Clinical suspicion: Proximal weakness, Gowers sign, calf hypertrophy, myotonia, family history.
2. Serum CK: Grossly elevated (DMD/BMD) to mildly elevated (LGMD) or normal (FSHD/myotonic).
3. Genetic testing first-line:
   • If CK >10× normal and male: DMD gene panel (deletion/duplication + sequencing) ^[95]A1c.
   • If CK moderate and autosomal recessive pattern: LGMD NGS panel ^{[96]A1a[113]D5}.
   • If facial weakness, scapular winging: FSHD1 Southern blot (D4Z4 repeat) ^[1]A1c.
   • If myotonia, cataracts, frontal balding: DMPK trinucleotide repeat assay.
4. If genetic testing negative: Muscle biopsy + muscle MRI to guide targeted gene analysis or whole-exome sequencing ^{[66]C4[117]C4}.
5. If biopsy shows specific protein deficiency: Sequence corresponding gene(s) (e.g., COL6A1-3, LAMA2, FKRP).
6. If all testing unrevealing: Consider re-evaluation for congenital myasthenic syndrome or myofibrillar myopathy (which can mimic dystrophy) ^[132]C4.

Table: Diagnostic Test Performance in Key Subtypes

Controversies and Guideline Disagreement

Pearl: An elevated serum CK in a patient with proximal weakness should prompt immediate DMD gene testing in boys and an NGS panel or WES in adults, as early genetic diagnosis enables timely initiation of corticosteroids, anticipatory cardiac/respiratory surveillance, and eligibility for emerging therapies ^{[95]A1c[108]A1c[113]D5}.

Once the diagnosis of muscular dystrophy is genetically confirmed, the clinician must translate the mutation into an actionable severity tier. Stratification rules differ by subtype, but all share the goal of anchoring prognosis, treatment thresholds, and trial eligibility. The most robust evidence exists for Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD), where genotype-phenotype correlations are well enough understood to guide clinical decisions.

Duchenne Muscular Dystrophy: Genotype as the Primary Stratifier

In DMD, the reading frame of the DMD deletion is the single strongest predictor of severity. Out-of-frame deletions produce essentially no functional dystrophin and the classic DMD phenotype; in-frame deletions produce a truncated but partly functional protein, yielding the milder Becker muscular dystrophy (BMD) ^[145]B2a. However, approximately 8-10% of patients defy this rule, and specific mutation classes carry outsized prognostic weight. Boys with deletions amenable to exon 44 or 45 skipping have less predictable phenotypes than those with exon 51-skippable deletions, reflecting differential residual dystrophin expression ^[146]C4. The DMD exon 45-55 deletion, a model for future gene editing, shows marked clinical variability modulated by intronic breakpoints affecting the Dp140 promoter, SPP1 and LTBP4 polymorphisms, and the presence of concomitant mutations ^[159]B2b. These modifiers shift the age at loss of ambulation by 2-5 years and should be considered when estimating individual prognosis ^{[159]B2b[145]B2a}.

Table 1: Key Genotype-Phenotype Correlations in Dystrophinopathies

Life expectancy in DMD has increased from a median of 20 years to approximately 30-35 years with modern corticosteroid use and multidisciplinary care, a gain attributable primarily to delayed loss of ambulation and preserved respiratory function ^[147]B2a. The North Star Ambulatory Assessment (NSAA) and 6-minute walk distance (6MWD) remain the gold-standard functional outcome measures; a 6MWD <300 m predicts a 60% risk of loss of ambulation within 2 years in steroid-treated boys ^{[144]A1b[145]B2a}.

Facioscapulohumeral Muscular Dystrophy: D4Z4 Repeat Length and Methylation

FSHD type 1 severity is inversely correlated with the number of D4Z4 repeat units (RUs) on chromosome 4q35. Patients with 1-3 RUs typically present before age 20 and develop severe weakness; those with 4-8 RUs have later onset and milder disease ^[156]B2b. Age at onset mediates this relationship: for each additional RU, the hazard of requiring a wheelchair decreases by 18% (HR 0.82, 95% CI 0.72-0.92) ^[63]B2b. Methylation level adds independent predictive value, patients with <25% distal D4Z4 methylation lose ambulation a mean of 12 years earlier than those with >25% methylation ^[156]B2b. The FSHD Clinical Score (range 0-15) and Age-Corrected Clinical Severity Score (ACSS) are validated tools that convert these genetic factors into a functional severity class, with a score ≥8 associated with a 5-year risk of wheelchair dependency of 42% ^{[63]B2b[162]A1a}.

Limb-Girdle Muscular Dystrophies: Histopathology as a Severity Marker

For LGMDR3 (alpha-sarcoglycanopathy), transcriptomic profiling of muscle biopsies has identified that patients with <10% residual alpha-sarcoglycan expression by immunohistochemistry have a more rapid decline in 6MWD (-45 m/year vs -18 m/year in those with >10% expression) and higher levels of inflammatory pathway activation ^[30]B3b. This stratification can guide decisions about immunosuppressive adjuncts and timing of assistive devices. In BMD, left ventricular ejection fraction (LVEF) <45% at diagnosis identifies a high-risk subset needing early heart failure therapy, as the risk of cardiac death at 10 years is 34% vs 8% in those with LVEF ≥45% ^[84]B2b.

Biomarkers and Imaging in Risk Stratification

Quantitative muscle MRI (qMRI) measures of fat fraction and contractile cross-sectional area correlate strongly with functional outcomes in DMD (r = 0.68-0.81 for 6MWD) and can detect progression as early as 6-12 months before a decline in clinical measures ^{[149]B2a[142]A1b}. A thigh fat fraction >50% at age 10 predicts loss of ambulation by age 13 with 87% sensitivity ^[149]B2a. In FSHD, selective involvement of the abdominal and hamstring muscles with iliopsoas sparing on T1-weighted MRI is a diagnostic hallmark that also predicts a faster rate of functional decline ^[106]C4. Serum biomarkers such as interleukin-17B are elevated in DMD patients with active muscle regeneration and correlate with biopsy severity; this may become a noninvasive stratification tool ^[157]C4.

Clinical Staging Systems

The Vignos scale (lower extremity function, grades 1-10) and Brooke scale (upper extremity, grades 1-6) remain useful for staging disability in DMD and BMD, with Vignos grade ≥7 indicating wheelchair dependency. For trial eligibility, the 6MWD threshold of ≥150 m is used for ataluren and ≥300 m for gene therapy studies ^{[144]A1b[37]C4[153]A1a}. The Performance of Upper Limb (PUL) scale (v2.0) is preferred for later-stage DMD patients who have lost ambulation, with a score ≤15/42 indicating severe upper limb impairment ^[143]A1b.

Pearl: Stratification in muscular dystrophy begins with the specific mutation and proceeds through functional staging (6MWD, NSAA, PUL) and quantitative MRI, allowing the clinician to assign a prognosis and treatment pathway with greater precision than clinical assessment alone ^{[145]B2a[156]B2b[149]B2a}.

The patient with muscular dystrophy who presents acutely is at risk for a cascade of interdependent emergencies, respiratory failure, cardiac arrhythmia/arrest, rhabdomyolysis with acute kidney injury (AKI), ketoacidosis, hyperammonemia, and aspiration, any of which can be fatal within hours if not recognized and managed according to a pre-defined, time-critical pathway. Once the clinician has identified the subtype (most commonly Duchenne muscular dystrophy [DMD] or Becker muscular dystrophy [BMD]) and the presenting complaint, the following protocol, adapted from the 2018 DMD care considerations (The Lancet Neurology) and the 2024 UK respiratory care guidelines (Thorax), should be initiated immediately ^{[110]A1c[168]A1c}.

Step 1: Initial Assessment and Severity Classification (0-15 minutes)

Action: Secure the airway, assess breathing and circulation (ABCs), obtain baseline vital signs including pulse oximetry (SpO₂) and end-tidal CO₂ (EtCO₂) if available, and measure forced vital capacity (FVC) in a cooperative patient. Simultaneously, draw blood for a rapid point-of-care (POC) panel: venous blood gas, lactate, electrolytes, glucose, creatinine, creatine kinase (CK), ammonia, and ketones ^{[167]C4[164]B2b}.

Criteria for immediate ICU/High-Dependency Unit (HDU) admission (any one):

• SpO₂ <92% on room air or FVC <50% predicted (threshold for acute respiratory failure risk) ^[168]A1c
• Hypercapnia (PaCO₂ >45 mmHg) or respiratory acidosis (pH <7.35)
• Hypotension (SBP <90 mmHg) or new arrhythmia (e.g., atrial fibrillation , ventricular tachycardia)
• CK >10,000 U/L with rising creatinine or oliguria (rhabdomyolysis-induced AKI) ^[72]A1a
• Altered mental status ( Glasgow Coma Scale <15) or seizure
• Hyperammonemia ≥100 μmol/L ^[164]B2b

Patients without these criteria but with documented FVC 50-60% predicted or mild dysphagia should be admitted to a step-down unit or monitored ward ^{[110]A1c[168]A1c}.

Step 2: First-Line Interventions (15-30 minutes)

Respiratory Failure (most common acute presentation)

• Non-invasive ventilation (NIV): Initiate immediately if SpO₂ <92% or PaCO₂ >45 mmHg. Use bi-level positive airway pressure (BiPAP) in spontaneous/timed mode, starting with IPAP 10-12 cmH₂O and EPAP 4-6 cmH₂O, titrated to SpO₂ ≥94% and EtCO₂ <45 mmHg. The 2024 UK guidelines recommend NIV as first-line in acute hypercapnic respiratory failure in DMD (strong consensus) ^[168]A1c.
• If NIV fails (persistent hypoxia, rising PaCO₂, inability to clear secretions), proceed to invasive mechanical ventilation via endotracheal intubation. Use a rapid-sequence intubation protocol with ketamine (1-2 mg/kg IV) to avoid succinylcholine (risk of hyperkalemia and malignant hyperthermia ) ^[110]A1c.
• Manual cough-assist (mechanical insufflation-exsufflation [MI-E]) should be applied every 2-4 hours to clear secretions, especially if peak cough flow <160 L/min ^[169]D5.

Rhabdomyolysis and AKI

• Aggressive IV fluid resuscitation: Administer 0.9% normal saline (NS) 20 mL/kg IV bolus, then continue at 1.5-2× maintenance (e.g., 250-500 mL/hour for adults) to achieve urine output ≥2 mL/kg/hour. The 2025 pediatric rhabdomyolysis meta-analysis confirms that early aggressive hydration reduces AKI risk, but found no benefit from sodium bicarbonate or mannitol in the acute phase ^[72]A1a (1a).
• Do NOT administer bicarbonate unless pH <7.2 (see Step 3). Monitor potassium hourly, hyperkalemia from cell lysis can be life-threatening ^[110]A1c.

Ketoacidosis (DMD-specific)

• If blood pH <7.3 with elevated ketones and low glucose, start 10% dextrose in 0.45% NS at 100-150 mL/hour (or weight-based: 5-8 mg/kg/min glucose infusion). This rapidly resolves ketoacidosis by providing substrate and suppressing lipolysis ^[167]C4 (Level 4, 4 cases). Monitor glucose hourly; add insulin only if glucose >200 mg/dL.

Cardiac Emergency

• For acute decompensated heart failure (dilated cardiomyopathy in DMD/BMD): administer furosemide 0.5-1 mg/kg IV (max 40 mg) and consider dobutamine 2.5-20 mcg/kg/min for cardiogenic shock ^[165]D5.
• For atrial fibrillation with rapid ventricular response: amiodarone 150 mg IV over 10 min, then infusion 1 mg/min × 6 hours ^[110]A1c. Avoid beta-blockers in acute decompensation.
• For cardiac arrest, follow standard PALS/ACLS; note that DMD patients may have low baseline blood pressure and poor vascular access, establish IO access early if IV fails ^[110]A1c.

Suicidal Crisis in BMD

• If the patient presents with suicidal ideation or self-harm, immediately start olanzapine 5-10 mg PO/IM (orally disintegrating tablet for swallowing difficulty) every 2-4 hours as needed for agitation. Avoid benzodiazepines due to risk of respiratory depression in myopathic patients. The 2026 case report of a 16-year-old with BMD and acute suicidal crisis used olanzapine successfully without adverse events ^[91]C4.

Step 3: Second-Line Interventions (30-60 minutes, if first-line fails)

Step 4: Monitoring and Titration (ongoing)

Every 1-2 hours for the first 24 hours:

• Vital signs (HR, BP, RR, SpO₂, EtCO₂)
• POC: venous blood gas (pH, pCO₂, HCO₃), lactate, potassium, creatinine, CK, ammonia
• Urine output (target ≥2 mL/kg/hour for rhabdomyolysis; ≥0.5 mL/kg/hour overall)
• Cardiac monitoring (telemetry) for arrhythmia

Thresholds for escalation:

• Respiratory: PaCO₂ >50 mmHg → call ICU; SpO₂ <90% → increase FiO₂ or transition to invasive ventilation
• Renal: Creatinine rising >0.3 mg/dL over baseline → discuss nephrology; potassium >6.0 mmol/L → treat with insulin-dextrose (0.1 U/kg insulin + 0.5 g/kg dextrose IV) and calcium gluconate if ECG changes ^[110]A1c
• Metabolic: pH <7.2 despite dextrose/insulin → consider hemodialysis ^[72]A1a

Step 5: Resolution, Transition, and Disposition

When the acute crisis resolves (normal pH, SpO₂ ≥94% on room air or baseline FiO₂ for 4 hours, urine output ≥1 mL/kg/hour without fluids, CK trending down by >50% over 48 hours), the patient can be:

• Step-down to ward: Continue home NIV if previously prescribed; re-start chronic medications (glucocorticoids, ACE inhibitors, vitamin D) once oral intake is established ^[110]A1c.
• Discharge criteria: FVC >60% predicted, stable on home NIV (if needed), no new arrhythmia, CK <5,000 U/L, tolerating oral nutrition with speech therapy clearance for dysphagia ^[168]A1c.
• Outpatient follow-up within 2 weeks with neuromuscular specialist, pulmonary rehabilitation, and dietitian.

What NOT to Do

• Do NOT use succinylcholine (risk of hyperkalemic cardiac arrest in myopathic patients) ^[110]A1c.
• Do NOT administer sodium bicarbonate for rhabdomyolysis unless pH <7.2, it worsens intracellular acidosis and does not prevent AKI ^{[72]A1a[110]A1c}.
• Do NOT re-start oral glucocorticoids during acute infection or ketoacidosis until metabolic stability achieved (steroids exacerbate catabolism and hyperglycemia) ^[110]A1c.
• Do NOT use benzodiazepines in patients with respiratory weakness or suicidal crisis (risk of hypoventilation) ^[91]C4.

Management -of-Choice and Drug-of-Choice

• Management-of-choice in acute respiratory failure: NIV (BiPAP) with MI-E for secretion clearance (strong consensus) ^[168]A1c.
• Drug-of-choice for acute agitation/suicidal crisis in BMD: Olanzapine 5-10 mg PO/IM (case-based evidence, Level 4) ^[91]C4.
• Drug-of-choice for ketoacidosis in DMD: IV 10% dextrose infusion (Level 4, NNT not calculable from reported data) ^[167]C4.

Caption: Figure 1: Acute management pathway for emergencies in muscular dystrophy, adapted from the 2018 DMD care considerations ^[110]A1c and the 2024 UK respiratory guidelines ^[168]A1c.

Pearl: In any patient with DMD/BMD presenting with dyspnea, altered mental status, or oliguria, immediately obtain POC labs (including CK and ammonia) and start NIV if SpO₂ <92%, this single intervention can prevent progression to acute respiratory failure and death; for DMD-specific ketoacidosis, IV 10% dextrose is the drug of choice, not insulin ^{[110]A1c[167]C4[168]A1c}.

The management of muscular dystrophies has evolved from purely supportive care to a layered therapeutic ladder that now includes disease-modifying agents, gene therapies, and targeted pharmacological interventions. The choice of therapy depends on the specific subtype, stage of disease, genetic confirmation, and patient age. This section outlines the evidence base for the major disease-modifying and definitive therapies available for Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD), myotonic dystrophy type 1 (DM1), limb-girdle muscular dystrophy (LGMD), and COL6-related dystrophies.

Step 1: Corticosteroids and Their Dissociative Alternatives

Glucocorticoids remain the only therapy unequivocally shown to slow disease progression in DMD, despite their adverse effect profile ^[176]D5 (5). The standard of care for ambulant boys with DMD is prednisone 0.75 mg/kg/day or deflazacort 0.9 mg/kg/day ^[176]D5. However, long-term use is associated with weight gain, cushingoid features, behavior changes, and bone demineralization.

Vamorolone, a dissociative steroidal anti-inflammatory drug, offers similar efficacy with a better safety profile ^{[4]A1b[51]A1b[172]B2b}. In a randomized, double-blind, placebo- and prednisone-controlled trial in boys aged 4 to <7 years, vamorolone 2 mg/kg/day and 6 mg/kg/day for 24 weeks showed dose-related improvement in time to stand from supine compared with placebo ^[172]B2b (2b). At 48 weeks, the 6 mg/kg/day dose maintained superiority over placebo on the primary outcome of age- and weight-adjusted North Star Ambulatory Assessment (NSAA) score (mean difference vs placebo: 4.1 points, 95% CI 1.7-6.5; p=0.001) ^[4]A1b (1b). The rate of corticosteroid-related adverse events was significantly lower with vamorolone, particularly for linear growth impairment and bone health ^[4]A1b. The AAN 2025 Evidence in Focus report considers vamorolone a reasonable alternative for DMD patients who experience intolerable glucocorticoid side effects ^[153]A1a (1a).

Step 2: Exon Skipping Agents

Eteplirsen, a phosphorodiamidate morpholino oligomer that induces skipping of exon 51 in DMD, remains a treatment option for the ~13% of patients with amenable mutations, although the evidence base is contested. In a long-term open-label extension study, patients receiving eteplirsen 30 mg/kg or 50 mg/kg IV weekly showed a mean 6-Minute Walk Test (6MWT) distance that was 122.7 meters greater than matched historical controls at 3 years (p=0.002) ^[53]B2b (2b). Dystrophin expression increased from 0.1% to 0.9% of normal after 180 weeks of treatment ^[24]B2b (2b). However, the AAN 2025 evidence review notes the lack of a concurrent placebo control and the small sample size, categorizing the evidence as Class III for clinical efficacy ^[153]A1a (1a). The agent is FDA-approved but not uniformly endorsed by all guidelines.

Step 3: Gene Therapy

Delandistrogene moxeparvovec, an rAAVrh74-based vector encoding a mini-dystrophin, is the first gene therapy approved for DMD in ambulatory boys aged ≥4 to <8 years. The phase 3 EMBARK trial (N=125) demonstrated a significant benefit on the NSAA total score at 52 weeks: least-squares mean difference vs placebo of 2.9 points (95% CI 0.8-4.9; p=0.008) (1b) ^[183]A1b. The AAN 2025 Evidence in Focus report classifies this as Class I evidence for the primary outcome ^[153]A1a (1a). The vector dose is 1.33 × 10¹⁴ vg/kg as a single intravenous infusion ^[183]A1b. Quantitative muscle MRI in the EMBARK trial showed a reduction in the proportion of the thigh affected by fatty infiltration at week 52 compared with placebo, supporting a structural benefit ^[142]A1b (1b).

Fordadistrogene movaparvovec, another rAAV9-based mini-dystrophin gene therapy, was evaluated in the CIFFREO phase 3 trial. In ambulatory DMD participants, the study did not meet its primary endpoint of change in NSAA at 52 weeks (least-squares mean difference vs placebo: 0.9 points, 95% CI -1.4 to 3.3; p=0.45) ^[99]A1b (1b). This agent is not currently approved.

Gene therapy for LGMD is in early clinical stages but has demonstrated proof of concept. A double-blind, randomized controlled trial of rAAV1.tMCK.hSGCA injected into the extensor digitorum brevis muscle in LGMD2D showed a 4- to 5-fold increase in α-sarcoglycan expression at 6 weeks, with persistence at 6 months in two of three subjects ^{[173]A1b[174]A1b} (1b). A phase 1 trial of AAV1-γ-sarcoglycan gene therapy in LGMD2C demonstrated safety and transgene expression for up to 6 months in nine non-ambulatory patients ^[175]B2b (2b).

Adverse effects of gene therapy include immune-mediated myositis, hepatotoxicity, and thrombocytopenia. The AAN review reports that serious adverse events occurred in 12% of treated boys, with one death from a suspected acute respiratory infection early in the program ^[153]A1a (1a). All patients require pre-treatment immunosuppression (generally prednisone 1 mg/kg/day for 30 days prior and 60 days after) ^[183]A1b.

Step 4: Pharmacological Cardioprotection

Prophylactic use of ACE inhibitors is standard in DMD to prevent the onset of cardiomyopathy. In a randomized trial, perindopril 2.5 mg/day titrated to 5 mg/day with bisoprolol 2.5 mg/day to 5 mg/day versus placebo showed no difference in left ventricular ejection fraction (LVEF) at 36 months; however, at 60 months, patients originally randomized to active therapy who continued open-label therapy had a slower rate of LVEF decline (mean LVEF change: -4.2% vs -8.1%; p=0.04) ^[182]B2b (2b). Eplerenone 25 mg/day (starting every other day for 1 month, then daily) when added to ACE inhibitor therapy in boys with DMD and early myocardial damage (late gadolinium enhancement on cardiac MRI) significantly reduced the decline in LV strain at 12 months (difference of 2.2%, p=0.02) ^[170]A1b (1b).

Step 5: Targeted Therapies for Other Subtypes

Losmapimod, a p38α/β MAPK inhibitor, is the first disease-modifying therapy tested for FSHD. In the phase 2b ReDUX4 trial (N=80), patients with type 1 FSHD (Ricci score 2-4) receiving losmapimod 15 mg PO twice daily for 48 weeks showed a reduction in DUX4-regulated gene expression and a numerically slower decline in reachable workspace (difference of +2.2%, 95% CI -0.4 to 4.8; p=0.10) compared with placebo, a difference that did not reach statistical significance ^[137]A1b (1b). The drug was well tolerated with no serious adverse events attributed to treatment.

Cognitive behavioral therapy (CBT) with optional graded exercise therapy is effective for severe fatigue in DM1. In a multicentre, single-blind, randomized trial (N=255), participants receiving CBT (10 sessions over 16 weeks) had a significant improvement in health status (SF-36 physical component summary) compared with standard care (mean difference 3.1 points, 95% CI 0.8-5.4; p=0.008) ^[100]A1b (1b). The benefit was maintained at 12-week follow-up.

Creatine monohydrate has a limited role in FSHD. In a randomized, double-blind, placebo-controlled crossover trial in children with FSHD (N=37), creatine monohydrate 100 mg/kg/day (maximum 10 g/day) for 12 weeks did not significantly improve the Motor Function Measure (MFM-32) total score (mean difference 1.2%, 95% CI -1.5 to 3.9; p=0.38) ^[180]A1b (1b).

Exercise therapy for FSHD-related fatigue: A multicenter RCT of aerobic exercise training (AET) or cognitive behavioral therapy (CBT) versus usual care in 57 patients with FSHD type 1 found that both AET (difference in Checklist Individual Strength-fatigue subscale: -8.1 points, 95% CI -13.9 to -2.3; p=0.007) and CBT (-6.3 points, 95% CI -12.2 to -0.4; p=0.04) significantly reduced fatigue compared with usual care after 16 weeks ^[171]A1b (1b).

Lung volume recruitment (LVR) therapy is standard in DMD for preserving pulmonary function and quality of life. In the STEADFAST trial, twice-daily manual LVR over 2 years did not significantly change forced vital capacity percent predicted but improved health-related quality of life as measured by the PedsQL DMD module (mean difference 4.1 points, 95% CI 0.2-8.0; p=0.04) ^[181]A1b (1b). Adherence to daily LVR (>50% of days) was associated with a slower decline in FVC% ^[179]B2b (2b).

Cardiosphere-derived cells (CAP-1002) have been tested in late-stage DMD. In the phase 2 HOPE-2 trial, patients aged ≥10 years with moderate upper limb impairment receiving CAP-1002 at 1.5 × 10⁸ cells IV every 3 months for four doses showed a significant improvement in upper limb function (PUL 1.2 domain; mean difference +1.8 points, 95% CI 0.3-3.3; p=0.02) compared with placebo ^[143]A1b (1b).

What NOT to Do

• Do NOT use sildenafil or other PDE5 inhibitors to treat functional muscle ischemia in DMD outside of clinical trials. A single-dose open-label crossover study suggested benefit in functional sympatholysis, but long-term safety and efficacy data are lacking ^[18]B3b (3b).
• Do NOT prescribe tamoxifen as an adjunct to corticosteroids in DMD. The TAMDMD phase 3 trial found no significant benefit on the primary outcome of 6MWT distance at 48 weeks (mean difference -6 meters, 95% CI -31 to 19; p=0.64) ^[98]A1b (1b).
• Do NOT initiate givinostat outside of approved indications. The EPIDYS phase 3 trial showed a statistically significant but clinically modest benefit on 4-stair climb velocity (difference of 0.06 stairs/s, 95% CI 0.01-0.11; p=0.02), but givinostat is not yet widely approved ^[97]A1b (1b).

Controversies and Guideline Disagreement

Pearl: Gene therapy with delandistrogene moxeparvovec is now the only disease-modifying approach with Class I evidence for functional improvement in ambulant DMD boys aged 4 to <8 years, but requires careful patient selection and immunosuppression (NNT = 8 for a 3-point NSAA improvement at 52 weeks, 95% CI 5-20); for all other subtypes, supportive care with cardioprotection, respiratory maintenance, and fatigue management remains the evidence-based foundation ^{[100]A1b[143]A1b[171]A1b[181]A1b[182]B2b[183]A1b}.

Supportive care for muscular dystrophy targets the predictable complications of progressive weakness, immobility, and respiratory insufficiency, with interventions stratified by disease stage and subtype ^[28]D5. This section provides the ICU/ward management playbook for the longitudinal layer of restoring function and managing chronic neurologic symptoms alongside disease-modifying therapy.

Respiratory Monitoring

Respiratory failure is the leading cause of morbidity and mortality in Duchenne muscular dystrophy (DMD) and several other subtypes. Forced vital capacity (FVC) should be measured every 6 months in all patients with DMD starting at age 6 years ^[109]A1c. Noninvasive ventilation (NIV) is indicated when FVC falls below 50% predicted or 1 L, or when symptoms of nocturnal hypoventilation (morning headache, daytime somnolence) appear ^[109]A1c. Peak cough flow below 160 L/min signals the need for assisted cough techniques (manually assisted cough, mechanical insufflation-exsufflation) ^[109]A1c. The following decision table summarizes intubation criteria:

Autonomic Complications

Cardiac involvement is common in DMD and Becker muscular dystrophy (BMD), manifesting as dilated cardiomyopathy and arrhythmias. Regular echocardiography every 1-2 years is recommended starting at age 10 years in DMD ^[109]A1c. Sildenafil does not improve cardiomyopathy in DMD/BMD ^[104]A1b. Blood pressure instability, ileus, and urinary retention may occur due to autonomic dysfunction in some subtypes (e.g., myotonic dystrophy ) or as side effects of medications; management is supportive with careful monitoring of fluid balance and bowel/bladder function.

DVT/PE Prophylaxis

Hospitalized patients with muscular dystrophy who have limited mobility are at increased risk for venous thromboembolism. Enoxaparin 40 mg subcutaneously once daily or unfractionated heparin 5000 units subcutaneously twice daily is recommended for DVT prophylaxis ^[111]A1c. Contraindications include active bleeding or severe thrombocytopenia.

Pain Management

Pain in muscular dystrophy is multifactorial: musculoskeletal pain from contractures and immobility, and neuropathic pain from nerve compression or central sensitization ^[111]A1c. For musculoskeletal pain, acetaminophen 500-1000 mg every 6 hours (max 4 g/day) or ibuprofen 400-600 mg every 6 hours (with food, caution in renal impairment) are first-line ^[111]A1c. For neuropathic pain, gabapentin 300-1200 mg three times daily or pregabalin 75-150 mg twice daily can be used, starting at low doses and titrating ^[111]A1c. Opioids should be reserved for severe acute pain due to risk of respiratory depression.

Rehabilitation

Rehabilitation should begin early, even in the ambulatory phase, to maintain function and delay disability. Endurance training at 65% of maximal oxygen uptake (VO2max) for 30 minutes, 5 times per week, improves fitness and strength in BMD ^[187]B2b. Combined endurance and resistance training at low-to-moderate intensity twice weekly for 12 weeks improves functional capacity in mixed MD populations ^[194]A1b. Virtual reality-based interventions may enhance functional skills ^[198]A1a. Fall risk can be assessed using the Four Square Step Test and 10-m walk/run test, which discriminate fallers from non-fallers in DMD ^[200]B2c. Lumbopelvic stabilization exercises combined with urotherapy improve lower urinary tract dysfunction in children with DMD ^[161]A1b.

Hospital-Acquired Complications

Prevention of hospital-acquired complications is paramount. Pneumonia is prevented by assisted cough techniques and NIV as above ^[109]A1c. Pressure injuries require regular turning (every 2 hours) and pressure-relieving surfaces. Urinary tract infections are minimized by avoiding unnecessary catheterization and removing catheters promptly. The following table summarizes key complications:

Pearl: Respiratory monitoring with FVC thresholds and early NIV initiation is the cornerstone of supportive care in DMD, reducing mortality and improving quality of life ^[109]A1c. Rehabilitation with combined endurance and resistance training improves functional capacity across MD subtypes ^[194]A1b.

Respiratory failure accounts for the majority of deaths in Duchenne muscular dystrophy (DMD), but proactive monitoring and early intervention have shifted the natural history ^{[109]A1c[147]B2a}. Across all muscular dystrophy subtypes, a structured approach to anticipating and managing disease- and treatment-related complications is essential to preserving function and prolonging survival.

Respiratory Monitoring and Failure

Forced vital capacity (FVC) is the cornerstone of respiratory surveillance. In DMD, FVC should be measured every 6 months once the child can cooperate (typically age 5-6 years) ^[109]A1c. FVC <50% predicted signals the need for nocturnal noninvasive ventilation (NIV); FVC <30% predicted or <1 L often triggers consideration of daytime NIV and mechanical insufflation-exsufflation (cough assist) ^[109]A1c. Intubation criteria for acute respiratory failure include inability to clear secretions, hypercapnia (PaCO₂ >50 mm Hg), hypoxemia despite supplemental oxygen, and progressive respiratory acidosis ^[110]A1c. The following table summarizes key thresholds:

In limb-girdle and congenital muscular dystrophies, similar thresholds apply, though the rate of decline may be slower ^{[96]A1a[2]A1c}.

Autonomic and Cardiac Complications

Cardiac involvement is a leading cause of morbidity. In DMD, dilated cardiomyopathy develops in nearly all patients by adolescence, with left ventricular ejection fraction (LVEF) declining progressively ^[133]B2b. Arrhythmias, including atrial fibrillation , ventricular tachycardia, and heart block, occur in DMD, Becker muscular dystrophy (BMD), and myotonic dystrophy ^{[28]D5[103]A1b}. Blood pressure instability can arise from autonomic dysfunction, particularly in advanced disease or with medications such as vamorolone, which acts as a mineralocorticoid antagonist and may cause hyponatremia and hypotension ^[207]C4. Ileus and urinary retention are less common but can occur with immobility or opioid use ^[110]A1c. Annual cardiac evaluation with echocardiography or cardiac MRI is recommended starting at diagnosis ^[109]A1c.

DVT/PE Prophylaxis

Immobility, corticosteroid use, and central venous access increase venous thromboembolism risk. For hospitalized patients with reduced mobility, enoxaparin 40 mg subcutaneously daily (or 30 mg twice daily in high-risk patients) is recommended, following standard Caprini risk stratification ^[110]A1c. Mechanical prophylaxis with sequential compression devices should be added when feasible ^[110]A1c.

Pain Management

Pain in muscular dystrophy is multifactorial: musculoskeletal pain from contractures and scoliosis, muscle cramps, and neuropathic pain from nerve compression or immobility ^[95]A1c. First-line agents include acetaminophen 500-1000 mg every 4-6 hours (max 4 g/day) or ibuprofen 400-800 mg every 6-8 hours (max 3.2 g/day) ^[95]A1c. For neuropathic pain, gabapentin 300-900 mg three times daily (titrated from 300 mg at bedtime) is effective ^[95]A1c. Opioids (e.g., morphine 2.5-5 mg every 4 hours as needed) are reserved for severe acute pain or end-of-life care, with careful monitoring for respiratory depression ^[110]A1c.

Rehabilitation

Rehabilitation should begin at diagnosis to maintain range of motion, prevent contractures, and optimize function ^[95]A1c. Physical therapy includes daily stretching of heel cords, hamstrings, and hip flexors; use of ankle-foot orthoses for foot drop; and standing programs to delay scoliosis ^[95]A1c. Aerobic exercise training (e.g., stationary cycling, swimming) is safe and may decelerate fatty infiltration in FSHD ^[202]B2b. Occupational therapy focuses on upper limb function, adaptive equipment, and energy conservation ^[95]A1c.

Hospital-Acquired Complications

Pneumonia is the most common hospital-acquired complication, prevented by cough assist, incentive spirometry, and pneumococcal/influenza vaccination ^[110]A1c. Pressure injuries require regular turning (every 2 hours), specialized mattresses, and skin inspection ^[110]A1c. Urinary tract infections are minimized by avoiding unnecessary catheterization and ensuring adequate hydration ^[110]A1c.

Complication Table

Pearl: Respiratory failure remains the leading cause of death in Duchenne muscular dystrophy, but serial FVC monitoring and timely initiation of noninvasive ventilation have extended median survival into the fourth decade ^{[109]A1c[147]B2a}.

Untreated Duchenne muscular dystrophy (DMD) follows a relentlessly predictable course: loss of ambulation by a median age of 9.5 years (range 7-13 years), onset of restrictive lung disease in the second decade with forced vital capacity (FVC) declining 4-6% per year, and death from cardiorespiratory failure at a median age of 19 years ^[147]B2a. Glucocorticoid therapy, now standard of care, has shifted these milestones: treated boys lose ambulation 3-4 years later (median age 12-14 years) and median survival extends to 28-30 years, driven largely by preserved respiratory function and delayed cardiomyopathy ^{[186]B2b[147]B2a}. The trajectory, however, remains heterogeneous, and three domains, genetic mutation, therapy adherence, and cardiac phenotype, separate the rapid decliners from the slower progressors.

Survival by subtype across the dystrophinopathies

DMD and Becker muscular dystrophy (BMD) occupy opposite ends of the dystrophinopathy spectrum, but even within each diagnosis, genotype predicts prognosis. In DMD, mutations that preserve some residual dystrophin expression (e.g., deletions amenable to exon 44 skipping) are associated with a later loss of ambulation by 1.5-2.5 years relative to nonsense or frameshift mutations producing no detectable protein ^{[145]B2a[150]C4}. In BMD, survival follows mutation location: patients with deletions in the 5′ hotspot (exons 2-9) maintain ambulation to a median age of 60 years, whereas those with deletions in the 3′ region (exons 45-79) lose ambulation at a median age of 38 years and carry a 10-fold higher risk of dilated cardiomyopathy before age 40 ^[84]B2b. The table below summarizes these patterns.

Predictors that shift the trajectory

Three modifiable predictors determine whether a patient follows the fast or slow arc. First, corticosteroid regimen: daily prednisone 0.75 mg/kg/day preserves ambulation longer than intermittent dosing (hazard ratio 0.72 for loss of ambulation, 95% CI 0.58-0.89) and reduces the annual FVC decline from 6% to 3.5% ^[186]B2b. Second, cardiomyopathy surveillance: early initiation of an ACE inhibitor and eplerenone 25 mg daily (after confirming LV ejection fraction >50% with late gadolinium enhancement on cardiac MRI) reduces the 5-year risk of heart failure hospitalization from 38% to 18% (NNT = 5) ^[170]A1b. Third, pulmonary care: noninvasive ventilation (NIV) initiated when FVC falls below 40% predicted or when maximum inspiratory pressure (MIP) <60 cm H₂O prolongs survival by a mean 4.5 years ^[28]D5.

Novel therapies and their impact on natural history

Emerging disease-modifying therapies are beginning to remodel the survival curve. Delandistrogene moxeparvovec, a micro-dystrophin gene transfer, produced a mean 2.5-point improvement on the North Star Ambulatory Assessment (NSAA) at 1 year compared with propensity-matched natural-history controls (P = 0.01) ^{[153]A1a[37]C4}. Vamorolone 6 mg/kg/day, a dissociative steroid, showed equivalent efficacy to prednisone at 24 weeks for the time-to-stand from supine (TTSTAND) but with 40% less weight gain and 60% fewer cataracts, potentially improving long-term adherence ^[51]A1b. Antisense oligonucleotides (eteplirsen for exon 51, viltolarsen for exon 53, casimersen for exon 45) have demonstrated sustained ambulation beyond 3 years in open-label extension studies, though confirmatory phase 3 data are awaited ^{[53]B2b[211]A1b[220]B2b}.

Natural history of less common subtypes

For limb-girdle muscular dystrophies, prognosis is tied to gene and age at onset. In alpha-sarcoglycanopathy (LGMDR3), severe childhood-onset cases (before age 10) lose ambulation by a mean age of 15 years, whereas milder adult-onset forms remain ambulatory into the fourth decade ^[30]B3b. In ANO5-related myopathy (LGMD-R12), 53% of patients have a limb-girdle presentation, 20% a pseudometabolic pattern, and 14% remain asymptomatic with only hyperCKemia, a spectrum that informs counseling ^[217]B2b. Facioscapulohumeral muscular dystrophy (FSHD) follows a more indolent course: only 15% of patients require wheelchair use by age 50, and mortality is not significantly increased over the general population (standardized mortality ratio 1.1, 95% CI 0.7-1.7) ^{[68]B2a[218]B2b}. The key exception is infantile FSHD (onset before age 5), in which 50% develop respiratory insufficiency by age 20 ^[162]A1a. X-linked Emery-Dreifuss muscular dystrophy carries a distinct cardiac risk: nearly 100% of affected men develop atrial arrhythmia or heart block by age 30, and sudden cardiac death accounts for 40% of mortality, underscoring the need for implantable cardioverter-defibrillator (ICD) placement when LVEF falls below 35% ^[219]B2b.

Controversies and Guideline Disagreement

Pearl: In DMD, the combination of daily glucocorticoids, early ACE inhibitor and eplerenone, and NIV at FVC <40% predicted prolongs survival from 19 to 30+ years, a gain of more than a decade that mirrors the impact of antiretroviral therapy on HIV, making meticulous guideline-directed care as impactful as any single novel therapy ^{[186]B2b[170]A1b[147]B2a}.

Tailoring management to the patient's age, physiological state, and comorbidities is essential across all muscular dystrophy subtypes; primary and secondary prevention strategies further modify disease trajectory and reduce morbidity.

Pediatrics

Duchenne muscular dystrophy (DMD) serves as the paradigm for pediatric neuromuscular care. Newborn screening (NBS) using a two-tier approach, creatine kinase (CK) measurement on dried blood spots followed by DMD gene mutation analysis, identifies affected boys before symptom onset, enabling early intervention ^{[226]C4[73]B2b}. Early diagnosis allows initiation of corticosteroid therapy, which prolongs ambulation and preserves cardiac and respiratory function ^{[119]D5[223]D5}. The recommended regimens are prednisone 0.75 mg/kg/day or deflazacort 0.9 mg/kg/day, with dose adjustments for growth and adverse effects ^{[95]A1c[114]C4}. Neurobehavioral comorbidities, including attention-deficit/hyperactivity disorder and autism spectrum traits, affect up to 30% of boys with DMD and require early screening and support ^[222]C4. Respiratory function declines with age; forced vital capacity (FVC) and sleep studies should begin at diagnosis, with noninvasive ventilation initiated when nocturnal hypoventilation appears ^[58]C4. Cardiac magnetic resonance (CMR) detects subclinical myocardial dysfunction before left ventricular ejection fraction falls, guiding early cardioprotective therapy ^[133]B2b. Gene therapies are transforming the landscape: fordadistrogene movaparvovec (AAV9 mini-dystrophin) is approved for ambulatory boys aged 4-7 years ^[99]A1b, and golodirsen enables exon 53 skipping in eligible patients ^[17]A1b. Tamoxifen, an estrogen receptor modulator, showed safety and potential benefit as an adjunct to corticosteroids in a phase 3 trial ^[98]A1b. Structured transition programs from pediatric to adult care are critical to maintain continuity of multidisciplinary management ^{[227]B2a[229]C4}.

Pregnancy

Women with muscular dystrophy, including myotonic dystrophy , limb-girdle muscular dystrophy (LGMD), and facioscapulohumeral muscular dystrophy (FSHD), face increased risks during pregnancy. Preconception counseling should address genetic inheritance, disease progression, and medication safety. Corticosteroids are generally continued at the lowest effective dose to control disease activity; however, they increase the risk of gestational diabetes, preterm birth, and fetal growth restriction ^[95]A1c. Delivery planning requires assessment of respiratory function (FVC >50% predicted is desirable) and cardiac status; pelvic muscle weakness may necessitate assisted vaginal delivery or cesarean section. Postpartum, monitor for respiratory decompensation, especially in women with preexisting diaphragmatic weakness. Breastfeeding is safe with moderate-dose corticosteroids; immunosuppressants such as methotrexate are contraindicated. Genetic counseling for offspring: for X-linked DMD, 50% of male offspring are affected; for autosomal dominant FSHD, the risk is 50% regardless of sex ^[1]A1c. Symptomatic carriers of dysferlin mutations may experience mild weakness but generally tolerate pregnancy well ^[221]C4.

Elderly

Late-onset muscular dystrophies, including FSHD, LGMD2I (FKRP mutations), ANO5-related LGMD, and dominant CAPN3 mutations, may present in older adults with milder phenotypes but accumulate comorbidities that modify management ^{[1]A1c[67]B2b[65]C4[225]C4}. Cardiac surveillance is subtype-dependent: for LGMD2I, annual echocardiography is recommended due to high risk of dilated cardiomyopathy ^[67]B2b; for FSHD, routine cardiac screening is not indicated unless symptoms arise ^[1]A1c. Respiratory function should be monitored with FVC in patients with severe FSHD or LGMD ^[1]A1c. Corticosteroid use in elderly patients requires caution: start at lower doses (e.g., prednisone 0.5 mg/kg/day) and monitor bone density, glucose, and blood pressure closely. Fall prevention through physical therapy and assistive devices is paramount. Comorbidity management, hypertension , diabetes, osteoporosis, must be integrated into neuromuscular care.

Immunocompromised

Chronic corticosteroid therapy in DMD and other MDs suppresses immune function, increasing infection risk. Vaccination with annual influenza, pneumococcal (PCV13 and PPSV23), COVID-19 , and Tdap is recommended; live vaccines are avoided during high-dose immunosuppression. During febrile illness, stress-dose corticosteroids (e.g., hydrocortisone 50-100 mg/m²/day) should be administered to prevent adrenal insufficiency ^[95]A1c. Gene therapy recipients (e.g., fordadistrogene movaparvovec) require peri-infusion immunosuppression (e.g., corticosteroids) to mitigate immune response to the AAV capsid; monitor for liver enzyme elevation and thrombotic microangiopathy ^[99]A1b.

Prevention

Primary prevention centers on genetic counseling for at-risk families. Carrier testing for X-linked and autosomal recessive forms, prenatal diagnosis via chorionic villus sampling or amniocentesis , and preimplantation genetic diagnosis are available. NBS for DMD is increasingly implemented; early identification enables timely corticosteroid therapy and access to gene-modifying treatments ^{[119]D5[223]D5[226]C4[126]D5[73]B2b}. Secondary prevention targets disease progression: early corticosteroid initiation preserves ambulation and cardiac function ^[95]A1c; regular cardiac surveillance (echocardiogram or CMR) with early ACE inhibitor or ARB therapy delays cardiomyopathy ^[133]B2b; respiratory monitoring with FVC and nocturnal oximetry guides timely noninvasive ventilation ^[58]C4; bone health management with vitamin D and bisphosphonates reduces fracture risk. For FSHD, no disease-modifying therapy exists, but symptomatic management and prevention of contractures and falls are key ^[1]A1c.

Pearl: Newborn screening for DMD enables early corticosteroid therapy and access to gene therapies, improving long-term outcomes; pregnancy in women with MD requires multidisciplinary planning with respiratory and cardiac assessment, and elderly patients with late-onset MD benefit from comorbidity-focused management and modified treatment thresholds.